ライフサイエンスコーパス: infected individual

1 distribution of the cases generated by each infected individual.

2 al becoming infected on contact with another infected individual.

3 sk from contact with oral secretions from an infected individual.

4 -restricted cellular immune responses in HIV-infected individuals.

5 ons (TAMs)) are rare in the virus from HIV-2-infected individuals.

6 that are susceptible to bNAbs isolated from infected individuals.

7 of infectious virus from reservoirs in HIV-1-infected individuals.

8 at Cx43 is dysregulated in the hearts of HIV-infected individuals.

9 uding among antiretroviral therapy-naive HIV-infected individuals.

10 shown to be present in sera from most HIV-1-infected individuals.

11 -infected individuals compared to HIV-1 mono-infected individuals.

12 voir will be necessary to eradicate HIV-1 in infected individuals.

13 ivalent to those in age-matched, chronically infected individuals.

14 M. tuberculosis-specific CD4 T cells in HIV-infected individuals.

15 fective cART, HIV-1 persists indefinitely in infected individuals.

16 eurological damage in virally suppressed HIV-infected individuals.

17 lowing clearance of peripheral virus in ZIKV-infected individuals.

18 d to broadly neutralizing antibodies in some infected individuals.

19 Env-specific antibodies in a minority of HIV-infected individuals.

20 syndrome (HUS), and adverse outcomes in STEC-infected individuals.

21 ar outnumber lymphocytes in the semen of HIV-infected individuals.

22 ted in an independent cohort of latently Mtb-infected individuals.

23 leading to increased fracture rate among HIV-infected individuals.

24 easing opportunities for timely treatment of infected individuals.

25 resent the most common type of cancer in HIV-infected individuals.

26 pment of a greater number of symptoms in WNV-infected individuals.

27 tion (FMT) as a potential therapeutic in HIV-infected individuals.

28 lec-1 in fuelling HIV-1 dissemination within infected individuals.

29 lasma sCD163 levels were measured in 933 HIV-infected individuals.

30 rvoir represents a barrier to cure among HIV-infected individuals.

31 alence estimates to published numbers of HIV-infected individuals.

32 portant determinant of media thinning in HIV-infected individuals.

33 of care in the clinical management of HIV-1-infected individuals.

34 s are available, they are ineffective in HPV-infected individuals.

35 to control HCV infection in the majority of infected individuals.

36 animal models and suppress viremia in HIV-1-infected individuals.

37 te of disease progression will vary in HIV-1 infected individuals.

38 on to evade immunity and reinfect previously infected individuals.

39 sonic activity is significantly lower in HIV-infected individuals.

40 n varies markedly in hepatitis C virus (HCV)-infected individuals.

41 hed and, importantly, how these vary between infected individuals.

42 unotherapeutic approaches in ART-treated HIV-infected individuals.

43 tified 2 human T-lymphotropic virus (HTLV)-4-infected individuals.

44 years), aviremic (<50 HIV RNA copies/ml) HIV-infected individuals.

45 thogen that causes mild to severe colitis in infected individuals.

46 oint host/pathogen genetic data from 541 HIV infected individuals.

47 dults and human immunodeficiency virus (HIV)-infected individuals.

48 ent among human immunodeficiency virus (HIV)-infected individuals.

49 dysfunctions at inflammatory tissue sites in infected individuals.

50 d this might be clinically beneficial to HIV-infected individuals.

51 high rates of cardiovascular disease in HIV-infected individuals.

52 thrombotic therapies should be tested in HIV-infected individuals.

53 Neurogenesis is impaired in HIV-infected individuals.

54 icative advantage and persist in chronically infected individuals.

55 directed bNAbs have been isolated from HIV-1-infected individuals.

56 thogen in human immunodeficiency virus (HIV)-infected individuals.

57 ion was detected in 28 out of 31 chronically infected individuals.

58 ion in macrophages, a key target of HIV-1 in infected individuals.

59 effusion lymphoma) primarily observed in HIV-infected individuals.

60 d be to expand the donor pool to include HIV-infected individuals.

61 diseases requires the accurate detection of infected individuals.

62 ng) stage sexual gametocytes in the blood of infected individuals.

63 idence in human immunodeficiency virus (HIV)-infected individuals.

64 mpairment continues to afflict almost 50% of infected individuals.

65 HIV-1 Gag p24 production in samples from HIV-infected individuals.

66 e sera will be relative to that of sera from infected individuals.

67 inical outcome and is highly variable across infected individuals.

68 to 30% of human immunodeficiency virus (HIV)-infected individuals.

69 between different groups of susceptible and infected individuals.

70 a problem affecting approximately 50% of HIV-infected individuals.

71 G for the treatment of early syphilis in HIV-infected individuals.

72 be large benefits to vaccinating previously infected individuals.

73 ciated with chronic immune activation in HIV-infected individuals.

74 gnitive dysfunction seen in well-treated HIV-infected individuals.

75 infection (HCV) commonly co-occur among HIV-infected individuals.

76 ibodies, whether engineered or isolated from infected individuals.

77 s one of the most common malignancies in HIV-infected individuals.

78 of new drugs aimed at eliminating HIV-1 from infected individuals.

79 .31% [24 of 726 samples]) than among non-HCV-infected individuals (0.30% [4 of 1,348 samples]).

80 significantly higher (P < 0.0001) among HCV-infected individuals (3.31% [24 of 726 samples]) than am

81 ly prolonged the time to AIDS onset in HIV-1-infected individuals, a functional cure has yet to be fo

82 In HIV-infected individuals after 96 weeks, no HIV- or treatmen

83 ges (but not T cells) of drug-suppressed HIV-infected individuals also contained abundant uracils.

84 tes to loss of immune control of LTBI in HIV-infected individuals, although the precise mechanisms wh

85 17, and Th22/Tc22 cells in 15 S. stercoralis-infected individuals and 10 uninfected individuals stimu

86 ogenesis have been noted in the brain of HIV-infected individuals and are likely linked to HIV-associ

87 Lymph node inflammation was higher in HIV-infected individuals and correlated with markers of vira

88 antibody response in a cohort of chronically infected individuals and found that a broadly neutralizi

89 ency, are elicited only in a small subset of infected individuals and have yet to be induced by vacci

90 cently identified in hepatitis C virus (HCV)-infected individuals and individuals who had received mu

91 ith an estimated 130-170 million chronically infected individuals and is the cause of serious liver d

92 ibodies elicited by the authentic virus from infected individuals and polyclonal antibodies from vacc

93 bs), and gp41 derived from chronically HIV-1-infected individuals and produced by hybridoma cells.

94 Using cells from HIV-1-infected individuals and reconstructed patient-derived d

95 ically in human immunodeficiency virus (HIV)-infected individuals and simian immunodeficiency virus (

96 urocognitive disorders afflict 30-50% of HIV-infected individuals and synaptodendritic injury remains

97 l inflammation was modestly increased in HIV-infected individuals and was positively correlated with

98 including human immunodeficiency virus (HIV)-infected individuals, and pulmonary colonization with P.

99 ss to affordable diagnostics to identify HBV-infected individuals, and to enable linkage to care and

100 Asymptomatic, chronically infected individuals are an oft-cited potential reservoi

101 Human immunodeficiency virus (HIV)-infected individuals are at increased risk of chronic ki

102 HIV-infected individuals are living longer on antiretroviral

103 ys capable of detecting antibodies in HPgV-2-infected individuals are needed to establish global sero

104 that a small proportion (<20%) of influenza infected individuals are responsible for the production

105 s assay cheaper when a large number of HIV-1 infected individuals are tested.

106 ) T cell clone isolated from an Mtb latently infected individual as a peptide from the Mtb protein, M

107 omparing IDU+/ HCV+ and IDU-/HCV- in 386 HIV-infected individuals as a discovery sample and in 412 in

108 d significantly higher HEV Ag in chronically infected individuals as compared to acutely infected pat

109 e of a differential effect of smoking in HIV-infected individuals as compared to uninfected individua

110 eral hundred sequences were obtained from an infected individual at seven time points over 2 years.

111 um and plasma samples were gathered from HCV-infected individuals at four international sites.

112 els could potentially be used to rank US HIV-infected individuals at higher or lower risk for CVD, th

113 Diabetes is not uncommon in HIV-infected individuals at the time of presentation to HIV

114 cells were measured longitudinally in 19 HIV-infected individuals before (median, 2 mo) and after ART

115 pletely dominates the microbiota not only in infected individuals but also in most individuals classi

116 munity is protective in the vast majority of infected individuals but can become detrimental if not f

117 py (ART) suppresses viral replication in HIV-infected individuals but does not eliminate the reservoi

118 ently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate

119 importance of routine HCV testing in all HIV-infected individuals, but especially in PWID.

120 heat pulses enhanced thermal tolerance among infected individuals, but the magnitude of the parasitis

121 rP(Sc)) that self-propagates in the brain of infected individuals by converting the normal prion prot

122 tion of the kinetics of HIV-1 suppression in infected individuals by passively administered 3BNC117,

123 However, in some cases, infected individuals can also experience hemorrhagic fev

124 1 gene sequences sampled longitudinally from infected individuals can reveal the evolutionary dynamic

125 ng longitudinal Env sequences from a clade C-infected individual (CAP256), we measured the impact of

126 R-122 and miR-200a are greater in HIV/HCV co-infected individuals compared to HIV-1 mono-infected ind

127 -analysis to estimate the odds of HCV in HIV-infected individuals compared with their HIV-negative co

128 fic CD4 T cells was markedly impaired in HIV-infected individuals, compared with HIV-uninfected indiv

129 served that plasma TNF-alpha levels in HIV-1-infected individuals correlated directly with VL levels

130 dendritic cells, from Plasmodium falciparum-infected individuals, correlated with lower parasitemia.

131 Within sorted lymph node cells from four HIV-infected individuals, CXCR5(+) subsets harbored 11-66-fo

132 HSPCs), which allows the virus to persist in infected individuals despite antiretroviral therapy.

133 ratio in human immunodeficiency virus (HIV)-infected individuals despite effective antiretroviral th

134 structural abnormalities were evident in HIV-infected individuals despite fully suppressive antiretro

135 ction with these viruses, only a minority of infected individuals develop a subsequent malignant tumo

136 However, some HIV-infected individuals develop bnAbs after approximately 2

137 H. pylori to understand how only a subset of infected individuals develop cancer.

138 All HIV-1-infected individuals develop strain-specific neutralizin

139 nging, but understanding how a subset of HIV-infected individuals develops bNAbs may guide immunizati

140 diagnostics for ZIKV are vital because ZIKV-infected individuals display no symptoms or nonspecific

141 Because recently infected individuals disproportionately contribute to th

142 nfection in which selection pressures within infected individuals drive rapid intrahost virus microev

143 s between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5

144 ring pregnancy could attenuate disease among infected individuals, especially in the context of antib

145 Human immunodeficiency virus (HIV)-infected individuals exhibit residual inflammation regar

146 How HSV evolves within an infected individual experiencing multiple episodes of re

147 M. tuberculosis-specific CD4 T cells in HIV-infected individuals expressed significantly higher leve

148 1 antiretroviral therapy in prolonging life, infected individuals face lifelong therapy because of a

149 l tracked human immunodeficiency virus (HIV)-infected individuals for 10 years following ART initiati

150 ould be included in routine screening of HIV-infected individuals for sexually transmitted infections

151 ral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly di

152 or novel specificities from HIV-1 subtype C infected individuals from India that can be exploited as

153 s collected from 70 virally suppressed HIV-1-infected individuals from Rakai District, Uganda, who ha

154 i individuals, in contrast to uninfected and infected individuals from the sympatric ethnic group Mos

155 Notably, CRF07_BC-infected individuals generated higher neutralization tit

156 who make up the largest population of HIV-1-infected individuals globally.

157 HIV-infected individuals had a higher proportion of total at

158 olonies in the spring, suggesting that virus-infected individuals had died during the winter.

159 Compared with HIV-negative MSM, HIV-infected individuals had significantly increased multipl

160 s to those with a mild fever and blisters on infected individuals' hands, feet, and throats to infect

161 nctional analysis of T-cell responses in HIV-infected individuals has indicated that virus-specific C

162 HIV-infected individuals have activated monocytes with an IF

163 ors that are increased in the serum of HIV-1-infected individuals have been suggested to directly or

164 HIV-infected individuals have excess congestive heart failur

165 ating persistent viral reservoirs from HIV-1-infected individuals have focused on CD4(+) T-cell reser

166 at central memory CD4 T cells (TCM) from HIV-infected individuals have heightened expression of BCL-2

167 llows for transplantation of organs from HIV-infected individuals (HIV+), provided it is performed un

168 -1-infected cells to ADCC by sera from HIV-1-infected individuals.IMPORTANCE HIV-1 evolved sophistica

169 n of infectious virus from reservoirs in HIV-infected individuals.IMPORTANCE The persistence of HIV r

170 7_BC-infected people with that of subtype B'-infected individuals in China.

171 This uPCR method identified most infected individuals in malaria-endemic areas.

172 he World Health Organization (WHO) for HIV-1-infected individuals in settings with high infectious di

173 HCV-infected individuals in the United States are at greater

174 ime PCR, using sera from a cohort of acutely infected individuals, in addition to a cohort of chronic

175 fectiveness and treatment outcomes for HIV-1-infected individuals, including children, worldwide.

176 Contact of fluids from infected individuals, including droplets or aerosols, wi

177 reactivation from its latent state within an infected individual is not known.

178 that can target the viral reservoir in HIV-1-infected individuals is a major goal of HIV-1 research.

179 A rare subset of HIV-1-infected individuals is able to maintain plasma viral lo

180 ratio in human immunodeficiency virus (HIV)-infected individuals is associated with inflammation and

181 quency in human immunodeficiency virus (HIV)-infected individuals is unknown.

182 exhausted T cells isolated from chronically infected individuals, little is known about when this st

183 arterial inflammation among ART-treated HIV-infected individuals may be needed.

184 ing and treatment of M. genitalium among HIV-infected individuals may be warranted to further underst

185 Human immunodeficiency virus (HIV)-infected individuals may have poorer serological respons

186 ted from extracellular vesicles in sera from infected individuals may provide a new tool for diagnosi

187 companying microbiota in Helicobacter pylori-infected individuals might affect disease progression an

188 Mortality in HIV-infected individuals might differ by sex and mode of HIV

189 at could compromise the health status of HIV-infected individuals might not be ethically warranted.

190 falciparum Ag-specific B cell subsets in HIV-infected individuals mirror those in the overall B cell

191 However, subtype B'-infected individuals mounted broader neutralization resp

192 ) T cells in HIV-uninfected (n = 20) and HIV-infected individuals (n = 20) with latent TB infection.

193 HIV-infected individuals (n = 97) had significantly greater

194 For a transmission event to occur, an infected individual needs to release infectious particle

195 individuals, or nonreactive results in HIV-1-infected individuals not on therapy, were observed and u

196 ng an overall co-infection prevalence in HIV-infected individuals of 6.2% (3.4-11.9).

197 rrence in a well-characterized cohort of HIV-infected individuals on antiretroviral therapy (ART) wit

198 f LRAs (panobinostat or vorinostat) to HIV-1-infected individuals on antiretroviral therapy induces a

199 y in which 15 virologically suppressed HIV-1-infected individuals on antiretroviral therapy received

200 In purified rCD4s from HIV-1-infected individuals on antiretroviral therapy, rapamyci

201 By increasing the proportion of HIV-infected individuals on ART from 30% to 50%, 686 new inf

202 These data show that TB recurrence, in HIV-infected individuals on ART is predicted by biomarkers o

203 Human immunodeficiency virus-infected individuals on cART (predominantly containing t

204 Additionally, HIV-infected individuals on cART remain at high risk of seri

205 icrobiomes of HIV-uninfected (HIV SN) to HIV-infected individuals on long-term ART (HIV+ LTART) from

206 that GS-9620 may be useful for treating HIV-infected individuals on suppressive antiretroviral thera

207 ral blood mononuclear cells (PBMCs) from HIV-infected individuals on suppressive antiretroviral thera

208 ote clearance of the macrophage reservoir in infected individuals on suppressive antiviral therapy.

209 dress the fecal bacterial communities in HIV-infected individuals on two ARV regimens from Mexico.

210 ns clearly differentiating infected from non-infected individuals or animals.

211 nt phagocytosis assays use IE collected from infected individuals or from in vitro cultures of P. fal

212 o primary data, samples of HCV or HIV-HCV co-infected individuals, or samples relying on self-reporte

213 t also more likely to report sex with an HIV-infected individual (p = 0.027).

214 Among HIV-1-infected individuals, particularly among those with mono

215 ariation in the number of cases generated by infected individuals, particularly found in spatially lo

216 ion of the serological status of potentially infected individuals, particularly pregnant women, can b

217 ment era, human immunodeficiency virus (HIV)-infected individuals, particularly those who initiated a

218 nclude targeted monitoring for SCC among HIV-infected individuals, particularly those with low CD4 co

219 of E. histolytica is the cyst, with a single infected individual passing up to 45 million cysts per d

220 rovided significant benefit for asymptomatic infected individuals (pooled incidence rate ratio, 0.62;

221 Helminth-infected individuals possess a higher risk of developing

222 Yet, in a small proportion of HIV-infected individuals, potent bnAb responses do develop,

223 DWMSAs in HIV-infected individuals presenting with neurological proble

224 miR-200a are elevated in ART-treated, HIV-1-infected individuals prior to the development of fatal l

225 mechanism by which some dengue virus (DENV)-infected individuals progress to severe disease is poorl

226 The cost of identifying 1 unaware HIV-infected individual ranged from US$51 to US$2,072 across

227 alysis of human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (A

228 evated in human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (A

229 Serial specimens from a trial of HIV-infected individuals receiving antiretroviral treatment

230 (HBV) has been reported in hepatitis C virus-infected individuals receiving direct-acting antiviral (

231 sponses in a longitudinal cohort of 15 HIV-1-infected individuals receiving systemic chemotherapy or

232 can occur in rare instances, the majority of infected individuals remain asymptomatic or present with

233 Although most immunocompetent infected individuals remain asymptomatic throughout life

234 ution with antiretroviral therapy (ART), HIV-infected individuals remain highly susceptible to tuberc

235 on of atypical MBC phenotypes found in HIV-1-infected individuals results from the loss of naive and

236 Lymph node cells from untreated HIV-infected individuals revealed that TFR cells harbored th

237 nalysis and direct genotyping of 4,233 HIV-1-infected individuals reveals two Glu88Ter homozygous and

238 ving through areas that previously contained infected individuals (right).

239 unique spectrum of disease depending on the infected individual's age and immunity.

240 pective cohort study of 45 chronically HIV-1-infected individuals sharing a similar demographics and

241 Although most herpes simplex virus 1 (HSV-1)-infected individuals shed the virus in their body fluids

242 c17, Th22/Tc22, and Tr1 cells in 26 filariae-infected individuals stimulated with filarial antigen fo

243 terferon for treatment of acute HCV in HIV-1 infected individuals (SWIFT-C) is an open-label, 2-cohor

244 After 48 weeks, HIV-infected individuals switching EFV to RAL showed decreas

245 e differences, we propose mapping the routes infected individuals take through "disease space." We fi

246 A subset of HIV-infected individuals termed elite controllers (ECs) main

247 a consistently higher HCV prevalence in HIV-infected individuals than HIV-negative individuals acros

248 may impact future therapy options for newly infected individuals, the clinical significance of the d

249 d the severity of neurological damage in HIV-infected individuals, the likelihood of cognitive impair

250 life and increased the life span of many HIV-infected individuals, this therapeutic strategy has seve

251 The rate of progression of HIV infected individuals to AIDS is known to vary with the g

252 need to specifically consider type among HIV-infected individuals to further understand MI outcomes a

253 y interrogating antibodies isolated from HIV-infected individuals to guide strategies aimed at develo

254 ockdown in resting CD4(+) T cells from HIV-1-infected individuals treated with antiretroviral therapy

255 reactive Aptima signal was observed in HIV-1-infected individuals under antiretroviral therapy.

256 The existence of HIV reservoirs in infected individuals under combined antiretroviral thera

257 ORTANCE The persistence of HIV reservoirs in infected individuals under effective antiretroviral trea

258 ndard of care for clinical monitoring of HIV-infected individuals undergoing antiretroviral therapy.

259 Twelve treatment-naive HIV-infected individuals underwent fludeoxyglucose F 18 ([18

260 and potency of NAb responses in 98 CRF07_BC-infected individuals using a large, multi-subtype panel

261 onal study), clinical scenario (asymptomatic infected individuals vs individuals after endoscopic res

262 Estimated movement of poliovirus-infected individuals was associated with the incidence o

263 Using convalescent plasma from DENV- and WNV-infected individuals, we found substantial enhancement o

264 etramer to detect AMA1-specific B cells, HIV-infected individuals were also shown to have a higher pr

265 from four fully ART-suppressed, chronically infected individuals were assayed at two time points sep

266 HIV type 1 (HIV-1)-infected individuals were eligible if they had a plasma

267 Compared with HIV-uninfected persons, HIV-infected individuals were slightly younger (mean age, 52

268 nts (LRA) in resting CD4(+) T cells from HIV-infected individuals were tested, the ultrasensitive p24

269 Approximately half of all MIs among HIV-infected individuals were type 2 MIs caused by heterogen

270 scription factor profiles were skewed in HIV-infected individuals where the proportion of T-bet(high)

271 disorders remain prevalent among HIV type 1-infected individuals, whereas our understanding of the c

272 Furthermore, HIV-infected individuals while on cART remain at an increase

273 ation of the gut is rarely achieved in HIV-1-infected individuals who are receiving clinically effect

274 stent infections, as exemplified by rare HIV-infected individuals who control the virus.

275 sequential lineages of trimers derived from infected individuals who developed bNAbs, and presenting

276 ca where Chagas disease is endemic and among infected individuals who have migrated to nonendemic are

277 ing referral; and overall proportions of HIV-infected individuals who knew their status (first 90 tar

278 The study subjects were HIV-1-infected individuals who presented with acute appendicit

279 We performed a survey including all HIV-infected individuals who received resistance testing in

280 We identified 33,005 HCV-infected individuals who received treatment, of whom 10,

281 matory predictors of bNAb development in HIV-infected individuals who spontaneously control HIV in th

282 and telomere length were assessed in 94 HIV-infected individuals who were aged >45 years and receivi

283 of unaware and viremic HIV-infected and HCV-infected individuals who were currently not being reache

284 can be dramatically reduced by treating the infected individual with antiretroviral therapy (ART).

285 These observations suggest that recently infected individuals with a delayed NAb response against

286 re recognized at 10-fold-lower levels in Mtb-infected individuals with a history of TB disease less t

287 In analysis that controlled for age, HIV-infected individuals with an undetectable viral load had

288 transcriptomes of monocytes derived from HIV-infected individuals with and without CI using genome-wi

289 n-label dose-finding study, we recruited HIV-infected individuals with cryptococcal meningitis who pr

290 een isolated from B cells of chronically HIV-infected individuals with detectable viremia.

291 s recently been detected in the brain of HIV-infected individuals with HIV replication in the periphe

292 rgeting strategies in the treatment of virus-infected individuals with impaired IFITM3 activity.

293 Studies treating HIV-1-infected individuals with latency reactivation agents to

294 gainst intra-subtype viruses than subtype B'-infected individuals with longer infection length.

295 CD4 T cell immunity that are impaired in HIV-infected individuals with LTBI, which may contribute to

296 HIV-1-infected individuals with protective HLA class I alleles

297 al blood mononuclear cells isolated from HIV-infected individuals with suppressed infection.

298 does not explain cognitive impairment in HIV-infected individuals with syphilis.

299 aphic and clinical characteristics among HIV-infected individuals with type 1 vs type 2 MIs.

300 r magnetic resonance at 1.5-T in treated HIV-infected individuals without known cardiovascular diseas